Teresa G Compton

US Patent:

6569616, May 27, 2003

Filed:

Jul 28, 2000

Appl. No.:

09/627986

Inventors:

Teresa Compton - Madison WI
Mary T. Huber - Portland OR

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

C12Q 170

US Classification:

435 5, 4241841, 4242301, 4242291

Abstract:

A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.

US Patent:

7147861, Dec 12, 2006

Filed:

Jun 26, 2002

Appl. No.:

09/942146

Inventors:

Teresa Compton - Madison WI, US
Mary T. Huber - Portland OR, US

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61K 39/345
A61K 39/245
A61K 39/255
G01N 33/549
C12P 21/06

US Classification:

4242041, 4242301, 424 931, 4242021, 424 932, 435 691, 435 71, 435 78

Abstract:

A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.

US Patent:

7491490, Feb 17, 2009

Filed:

May 12, 2005

Appl. No.:

11/127601

Inventors:

Teresa Compton - Madison WI, US
Adam Lloyd Feire - Madison WI, US

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

C12Q 1/70

US Classification:

435 5, 930 10

Abstract:

The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.

US Patent:

8586034, Nov 19, 2013

Filed:

Feb 11, 2009

Appl. No.:

12/369650

Inventors:

Teresa Compton - Madison WI, US
Adam Lloyd Feire - Madison WI, US

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A61K 39/395
A61K 39/00
A61K 39/42
A61K 39/12
A61K 39/35

US Classification:

4241301, 4242041, 4242291, 4242301, 4241391, 4241411, 4241471, 4241591

Abstract:

The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.

US Patent:

20070154882, Jul 5, 2007

Filed:

Mar 10, 2006

Appl. No.:

11/372840

Inventors:

Teresa Compton - Winchester MA, US
Samuel Gellman - Madison WI, US
Emily English - Madison WI, US
Robert Chumanov - Middleton WI, US

International Classification:

C12Q 1/70

US Classification:

435005000

Abstract:

Disclosed are beta-polypeptides that mimic the coiled-coil regions of gB and gH by display of the key hydrophobic residues for coiled-coil packing along one face of beta-polypeptide 12-helix. The most potent inhibitor blocks infection of CMV with an ICof approximately 20 m.

US Patent:

53246640, Jun 28, 1994

Filed:

Jan 21, 1993

Appl. No.:

8/007392

Inventors:

Jack H. Nunberg - San Carlos CA
Leonard E. Post - Ann Arbor MI
Teresa Compton - Madison WI
Erik A. Petrovskis - Ann Arbor MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C12N 1586
C12N 1538
A61K 4500

US Classification:

4353201

Abstract:

Methods for isolating thymidine kinase-encoding DNA of a herpes virus are described. These methods utilize degenerate primers based on regions of relatively conserved amino acid sequence in herpes virus thymidine kinase proteins to initiate a polymerase chain reaction which yields large amounts of the thymidine kinase-encoding DNA. The methods are illustrated in the isolation of the thymidine kinase gene of feline herpes virus, which can be used to construct recombinant thymidine kinase-negative feline herpes viruses for purposes of constructing live vaccines and expression vectors. In addition, the regulatory elements of the feline herpes virus thymidine kinase gene are useful in the construction of recombinant DNA vectors.

US Patent:

20170016919, Jan 19, 2017

Filed:

Feb 27, 2015

Appl. No.:

15/120573

Inventors:

- Cambridge MA, US
John P. Carulli - Southborough MA, US
Leonid Gorelik - Quincy MA, US
Teresa Compton - Concord MA, US

International Classification:

G01N 33/68
C12Q 1/68

Abstract:

The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).